Medicine & Health

Researchers at Washington University have developed a method to peer into biomolecular condensates, which could lead to a better understanding of condensate functions and their impairment in cancers and neurodegeneration.

Graham A. Colditz, MD, DrPH, the Niess-Gain Professor of Surgery and director of the Public Health Sciences Division in the Department of Surgery at WashU Medicine, has been awarded the Brinker Award for Scientific Distinction in Population Science.

The National Cancer Institute, part of the National Institutes of Health (NIH), has awarded Aimilia Gastounioti, an assistant professor at WashU Medicine, a five-year $3 million grant to improve breast cancer risk assessments for Black women.

Research from WashU Medicine found a possible new treatment strategy for certain types of blood cancers.

A phase 1 clinical trial co-led by researchers at WashU Medicine found that a new type of cell-based immunotherapy was safe for patients with several types of B-cell lymphoma, a type of blood cancer.

Nusayba Bagegni, MD, an associate professor at WashU Medicine, has been awarded a 2024 Early Career Cancer Clinical Investigator Award from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).

WashU Medicine has received renewal of a prestigious National Cancer Institute grant. Led by Daniel Link, MD, it provides funding for translational research into new therapies for patients with blood cancers.

Glioblastoma is an aggressive, incurable brain cancer that is the most common malignant brain tumor in adults. New research from Washington University in St. Louis shows that glioblastoma has an internal clock and syncs its daily rhythms to match — and take advantage of — the rhythms of its host.

A new, artificial intelligence-based method of analyzing mammograms, developed by researchers at WashU Medicine, identified individuals at high risk of developing breast cancer more accurately than the standard, questionnaire-based method did.

Results from a clinical trial conducted at WashU Medicine showed adding the investigational drug itacitinib to standard care for “half-matched” stem cell transplantation may reduce rates of graft-versus-host disease.